Researchers analyzed data from over 1,400 adults with type 2 diabetes to see how a specific drug combination affected their health. The study looked at patients who had or did not have fatty liver disease. They compared the use of dapagliflozin and pioglitazone together against standard care or using only one medication.
The results showed that the combined treatment helped lower HbA1c levels, fasting blood glucose, and post-meal glucose. Additionally, patients taking both medications saw a reduction in liver fat content and improved scores for liver activity. The study also noted higher rates of steatohepatitis resolution among those on the combination therapy.
While the results are promising, it is important to note that much of the liver data comes from non-invasive markers rather than direct tissue samples. Because the evidence relies on these indirect measures, the findings should be viewed with caution. This research shows a link between the medication combination and improved health markers, but more biopsy-confirmed data is needed to fully understand its impact on liver tissue.
